Anti-CD20 therapies, COVID-19 and vaccine readiness
Channel: Gavin Giovannoni
Date: 2020-05-22

This video puts forward a hypothesis that anti-CD20 therapies may reduce the risk of getting severe COVID-19, by blunting antibody responses to SARS-CoV-2. However, the downside of anti-CD20 therapies is that they may prevent vaccine responses to future SARS-CoV-2 vaccines. The talk also addresses optimizing the dose of anti-CD20 in terms of deep tissue and/or CNS penetration to target the real MS (disability progression and end-organ damage).